Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

using Renagel.

With today’s results, Genzyme has concluded that the powder formulation of Renvela dosed three times per day may represent a promising alternative for patients with chronic kidney disease. The company will continue to move ahead aggressively with clinical and regulatory plans for the powder formulation dosed three times per day, and these data will form part of an NDA submission in the first half of 2008.

“We are very pleased with the progress we have made to date in our multi-faceted development program for Renvela, including filing an NDA for patients on dialysis, completing a successful trial in the pre-dialysis population, and demonstrating the effectiveness of the powder formulation dosed three times per day,” said John P. Butler, president, Genzyme Renal. “Results of the once-per-day trial were greatly influenced by the strong phosphorus reduction seen in the Renagel arm, which was superior to that seen in all but one previously conducted clinical trials. While today’s results will not currently support a regulatory filing for once-per-day dosing, they are clinically meaningful and give us confidence that this approach can be effective. We will continue to work with regulatory authorities to design an appropriate clinical plan to gain approval for this dosing regimen.”

About Renvela

Renvela is a buffered form of Renagel, the most-prescribed phosphate binder in the United States. Like Renagel, Renvela is a calcium-free, metal-free, non-absorbed phosphate binder, and will be available as 800mg tablets once approved. A New Drug Application for Renvela is currently under review by the US Food and Drug Administration for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

In April, Genzyme announced that a new clinical trial showed that Renvela significantly reduced serum phosphorus, calcium-phosphorus product and LDL cholesterol in hyperphosphatem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
(Date:7/22/2008)...Pilot Study Suggests That Ekkyo,s New Approach of ...ally Improve Scar Healing Physiology, MARSEILLES,...nown as,Heatwave Technology) a photomedicine compa...ems for skin scar prevention and reduction, announ...in Lasers in Surgery and Medicine*,reporting the r...
Breaking Medicine Technology:Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 1Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 4JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 1JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 2JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 3JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 4ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 1ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 2ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 3Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 1Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 2Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 3
...Maintained Stability,Significantly Longer than Pla...Comparable with Placebo , MARIETTA, Ga. and COLLEG..., Inc., Wyeth Pharmaceuticals, a division of Wyeth...tudy results on,bifeprunox, an investigational tre...enia, today at the 2007 annual meeting of,the Amer...
...ire-FirstCall/ -- Forest,Laboratories, Inc. and Cy...inary top-line results from a 1,196 patient random...d pivotal Phase III,study demonstrate statisticall...s a treatment of fibromyalgia syndrome. At this ti...tial top-line,results and further analyses will be...
Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:7/25/2008)... jobs created in the medical field slowed in June,...d of slowdown: they laid off fewer people in June ... Seattle, WA (PRWEB) July 25, 2008 -- Though the ... in June overall, pharmaceutical companies reporte...to the ears of sales representatives: fewer layoff...
(Date:7/25/2008)... J. Reilly, Joins Aethon Team, PITTSBURGH, July 2...com ), the leading developer of mobile robotics fo... that Robert J. Reilly has,joined the company as S... Reilly, who was most recently Vice President -- G...y Pharmacy Division, brings more than 30,years of ...
(Date:7/25/2008)...se immune system changes , , FRIDAY, Jul...g gastroesophageal reflux disease (GERD) and asthm...enter researchers. , An association between the...since then studies have shown that between 50 perc...nce GERD symptoms. But the actual link between GER...
(Date:7/25/2008)... Association (DIA) and the Food and Drug Administr... (CPI) on the Move: Complexities and Challenges (S...th Transporter Workshop (October 2-3; North Bethes...RWEB) July 25, 2005-- The http://www.diahome.org/...d and Drug Administration (FDA) will host the htt...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3
...enge releases a dose of nicotine and is one of the...uit smoking.// The federal government has announc...nada. The lozenges are to join nicotine patches, g...er the counter. This decision was taken because th...
...re Commission today came down heavily on senior ma...were responsible for the spread of a lethal bug// ...gets above infection control. A couple of outbrea...pital resulted in 33 deaths far more than the 12 o...
...e-up of community health care could cause a change...e been made to merge the roles of community health...t nurses into one community health job. This could...ss Scotland. These were the plans that were outli...
...shington residents have taken ill after eating raw...t of Health has reported. The Health department ha...oid eating raw shellfish. Oysters that are prope...ut raw oysters may be prone to bacteria that is fo...
Other Medicine News:Health News:"Serious Failings" Led To Spread Of Lethal Hospital Bug 2
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Designed for applications that demand the utmost in biological purity, individually packed Finntip BioCon tips are endotoxin-free, DNA-free, DNase-free and RNase-free. Finntip BioCon tips are guaran
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting.
Medicine Products: